[Form 4] OPKO HEALTH, INC. Insider Trading Activity

Rhea-AI Filing Summary

OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D. reported multiple purchases of OPKO common stock on 11/18/2025. The transactions, coded as open-market or private purchases, ranged from $1.245 to $1.29 per share across several small trades.

Following these transactions, Frost is shown as beneficially owning 214,966,448 OPKO shares indirectly, as noted in a footnote describing Frost Gamma Investments Trust and related entities. Additional holdings of 3,568,951 shares are listed as directly owned, and 30,127,177 shares as indirectly owned through Frost Nevada Investments Trust, with both positions also accompanied by detailed ownership-disclaimer language. Frost is identified as a director, 10% owner, CEO and Chairman of OPKO Health.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		P		410	A	$1.245	214,386,858	I	See Footnote(1)
Common Stock	11/18/2025		P		49,590	A	$1.25	214,436,448	I	See Footnote(1)
Common Stock	11/18/2025		P		66,635	A	$1.255	214,503,083	I	See Footnote(1)
Common Stock	11/18/2025		A		46,700	A	$1.26	214,549,783	I	See Footnote(1)
Common Stock	11/18/2025		P		15,000	A	$1.265	214,564,783	I	See Footnote(1)
Common Stock	11/18/2025		P		1,772	A	$1.27	214,566,555	I	See Footnote(1)
Common Stock	11/18/2025		P		212,608	A	$1.275	214,779,163	I	See Footnote(1)
Common Stock	11/18/2025		P		69,728	A	$1.28	214,848,891	I	See Footnote(1)
Common Stock	11/18/2025		P		428	A	$1.2847	214,849,319	I	See Footnote(1)
Common Stock	11/18/2025		P		83,556	A	$1.285	214,932,875	I	See Footnote(1)
Common Stock	11/18/2025		P		1	A	$1.2859	214,932,876	I	See Footnote(1)
Common Stock	11/18/2025		P		33,572	A	$1.29	214,966,448	I	See Footnote(1)
Common Stock								3,568,951	D
Common Stock								30,127,177	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

1. Name and Address of Reporting Person^*

Frost Gamma Investments Trust

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

2. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

	Phillip Frost, M.D., Individually and as Trustee	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OPKO Health (OPK) report for 11/18/2025?

On 11/18/2025, OPKO Health reported that Phillip Frost, M.D. engaged in multiple purchases of common stock, with trades coded as purchases and prices ranging from $1.245 to $1.29 per share.

How many OPKO (OPK) shares did Phillip Frost beneficially own after the reported trades?

After the reported trades, Phillip Frost is shown as beneficially owning 214,966,448 OPKO common shares indirectly through entities described in Footnote 1, plus separate positions of 3,568,951 shares directly owned and 30,127,177 shares indirectly owned as described in Footnote 2.

At what prices did Phillip Frost buy OPKO Health (OPK) shares on 11/18/2025?

The reported OPKO share purchases by Phillip Frost on 11/18/2025 were executed at prices between $1.245 and $1.29 per share, with several individual trades at specific prices such as $1.245, $1.25, $1.255, $1.26, $1.265, $1.27, $1.275, $1.28, $1.2847, $1.285, $1.2859 and $1.29.

What is Phillip Frost’s relationship to OPKO Health (OPK)?

Phillip Frost, M.D. is identified as a director, a 10% owner, and an officer of OPKO Health, holding the titles of CEO & Chairman.

How are Phillip Frost’s indirect OPKO (OPK) holdings structured according to the filing?

Footnote 1 explains that 214,966,448 shares are held by Frost Gamma Investments Trust, with a chain of related entities in which Phillip Frost has interests. Footnote 2 explains that 30,127,177 shares are held by Frost Nevada Investments Trust through Frost-Nevada, L.P. In both cases, the reporting person states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.

Does the OPKO (OPK) Form 4 include any ownership disclaimers by Phillip Frost?

Yes. Both Footnote 1 and Footnote 2 state that the reporting person disclaims beneficial ownership of the referenced securities, except to the extent of any pecuniary interest, and that the report shall not be deemed an admission of beneficial ownership for Section 16 or any other purpose.